Lung cancer combo trial halted early – too few patients to draw conclusions

NCT ID NCT02257619

Terminated Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tested whether adding itacitinib to standard chemotherapy (docetaxel) could help people with advanced non-small cell lung cancer live longer. The trial was stopped early after enrolling only 9 participants, so we cannot tell if the combination is safe or effective. The main goal was to find the right dose and check for serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: itacitinib and docetaxel
What this could lead to: If it worked, this combination might have offered a new treatment option for advanced lung cancer patients who had already tried one prior chemotherapy.
What could go wrong: The trial was terminated early with only 9 participants, so we have very little data. It is unclear if itacitinib adds any benefit or causes more side effects than docetaxel alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CARCINOMA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC (NON-SMALL CELL LUNG CARCINOMA)

Contacts and locations

Locations

Study site

Hot Springs, Arizona, United States
Study site

Los Angeles, California, United States
Study site

Washington D.C., District of Columbia, United States
Study site

Orlando, Florida, United States
Study site

Detroit, Michigan, United States
Study site

Pascagoula, Mississippi, United States
Study site

Kansas City, Missouri, United States
Study site

Omaha, Nebraska, United States
Study site

Lebanon, New Hampshire, United States
Study site

Goldsboro, North Carolina, United States
Study site

Cleveland, Ohio, United States
Study site

Gettysburg, Pennsylvania, United States
Study site

Hershey, Pennsylvania, United States
Study site

Pawtucket, Rhode Island, United States
Study site

Spartanburg, South Carolina, United States
Study site

Round Rock, Texas, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.